General Information of the Ferroptosis Regulator (ID: REG10359)
Regulator Name NAD-dependent protein deacetylase sirtuin-3, mitochondrial (SIRT3)
Synonyms
SIR2L3; Regulatory protein SIR2 homolog 3; SIR2-like protein 3
    Click to Show/Hide
Gene Name SIRT3
Gene ID 23410
Regulator Type Protein coding
Uniprot ID Q9NTG7
Sequence
MAFWGWRAAAALRLWGRVVERVEAGGGVGPFQACGCRLVLGGRDDVSAGLRGSHGARGEP
LDPARPLQRPPRPEVPRAFRRQPRAAAPSFFFSSIKGGRRSISFSVGASSVVGSGGSSDK
GKLSLQDVAELIRARACQRVVVMVGAGISTPSGIPDFRSPGSGLYSNLQQYDLPYPEAIF
ELPFFFHNPKPFFTLAKELYPGNYKPNVTHYFLRLLHDKGLLLRLYTQNIDGLERVSGIP
ASKLVEAHGTFASATCTVCQRPFPGEDIRADVMADRVPRCPVCTGVVKPDIVFFGEPLPQ
RFLLHVVDFPMADLLLILGTSLEVEPFASLTEAVRSSVPRLLINRDLVGPLAWHPRSRDV
AQLGDVVHGVESLVELLGWTEEMRDLVQRETGKLDGPDK

    Click to Show/Hide
Family Sirtuin family
Function
NAD-dependent protein deacetylase. Activates or deactivates mitochondrial target proteins by deacetylating key lysine residues. Known targets include ACSS1, IDH, GDH, SOD2, PDHA1, LCAD, SDHA and the ATP synthase subunit ATP5PO. Contributes to the regulation of the cellular energy metabolism. Important for regulating tissue-specific ATP levels. In response to metabolic stress, deacetylates transcription factor FOXO3 and recruits FOXO3 and mitochondrial RNA polymerase POLRMT to mtDNA to promote mtDNA transcription. Acts as a regulator of ceramide metabolism by mediating deacetylation of ceramide synthases CERS1, CERS2 and CERS6, thereby increasing their activity and promoting mitochondrial ceramide accumulation.

    Click to Show/Hide
HGNC ID
HGNC:14931
KEGG ID hsa:23410
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
SIRT3 can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Unspecific Target [Unspecific Target]
In total 3 item(s) under this target
Experiment 1 Reporting the Ferroptosis Target of This Regulator [1]
Responsed Disease Ovarian dysfunction ICD-11: 5A80
Responsed Drug Metformin Investigative
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vivo Model
n = 6 blank control group was created. The mice in the control group were fed regular food and gavaged with normal saline daily. The mice in the control group were given a high-fat diet and 1 mg/kg of letrozole via gavage for 21 days to establish a PCOS model of insulin resistance and hyperandrogenism. The mice, after successful modeling, were randomly divided into PCOS group and metformin group (n = 6). During the treatment period, the control group continued to be fed with normal feed and given normal saline; the PCOS group was fed with continuous high-fat feed and given letrozole (1 mg/kg/day) by intragastric administration, and the metformin group was given metformin by intragastric administration (200 mg/kg/day). After 30 days of treatment, the experimental mice were euthanized, serum was collected, one mouse ovary was collected for histological examination, and the other was stored in a -80 refrigerator for molecular biology experimental research.

    Click to Show/Hide
Response regulation Morphological results showed that after metformin treatment, polycystic lesions in ovaries were reduced, the ovarian function was restored, and the expressions of SIRT3 and GPX4 were elevated. Metformin could regulate ferroptosis to improve polycystic ovary syndrome (PCOS) via the SIRT3/AMPK/mTOR pathway.
Experiment 2 Reporting the Ferroptosis Target of This Regulator [2]
Responsed Disease Cardiomyopathy ICD-11: BC43
Responsed Drug LCZ696 Approved
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model
CHO-S/H9C2 cells Normal Cricetulus griseus CVCL_A0TS
In Vivo Model
All animal protocols were approved by the Animal Care and Use Committee of TaizhouHospital, affiliated to Zhejiang University (Taizhou, China). Twenty-four 2-month-old male Wistar rats weighing 190-220 g were purchased from the Experimental Animal Center of Basi Medicine, Zhejiang Chinese Medical University. The animals were reared under a 12 h light/12 h dark cycle at a relative humidity of 55 ± 5% and temperature of 23 ± 2 , with unrestricted access to food and water. All animals were acclimatized to laboratory conditions for 1 week before the experiments and were randomly divided into four groups: control group (CG, n = 6); LCZ696 group (LCZ, n = 6); DOX group (DOX, n = 6); and DOX + LCZ696 group (DOX + LCZ, n = 6). The CG received saline solution by gavage for 6 weeks (2 mL/day), while the treatment groups received DOX (Cat. HY-15142A, MedChemExpress, USA), LCZ696 (Cat. HY-18204A, MedChemExpress, USA), or DOX + LCZ696. DOX was administered at a dose of 2.5 mg/kg once a week for 6 weeks via tailvein injection. LCZ696 (60 mg/kg/day) was administered by gavage for 6 weeks. Body weight was measured weekly.

    Click to Show/Hide
Response regulation LCZ696 treatment increased SIRT3 expression and deacetylated its target gene SOD2, and these changes were mediated by AKT activation. Collectively,LCZ696 prevents DOX-induced cardiotoxicity by inhibiting ferroptosis via AKT/SIRT3/SOD2 signaling pathway activation.
Experiment 3 Reporting the Ferroptosis Target of This Regulator [5]
Responsed Disease Intervertebral disc degeneration ICD-11: FA80
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Ubiquitin mediated proteolysis hsa04120
Cell Process Cell ferroptosis
In Vitro Model
HEK-293T cells Normal Homo sapiens CVCL_0063
HNP (Human nucleus pulposus cells)
In Vivo Model
8-10 weeks old male mice were placed in prone position and anesthetized with isoflurane inhalation. The 1.5 cm-long longitudinal incision was made in 2 mm from the posterior midline. The superior and inferior articular processes, supraspinous ligament and interspinous ligament of the L4-L5 lumbar vertebrae were removed to construct LSI, which would induce IVDD. After the operation, the mice were placed in a warm environment.

    Click to Show/Hide
Response regulation Overexpression of USP11 significantly ameliorate oxidative stress-induced ferroptosis, thus relieving intervertebral disc degeneration (IVDD) by increasing Sirt3. Moreover, knockout of USP11 in vivo (USP11) resulted in exacerbated IVDD and poor pain-related behavioral scores, which could be reversed by overexpression of Sirt3 in intervertebral disc.
Phospholipid hydroperoxide glutathione peroxidase (GPX4) [Suppressor]
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis Target of This Regulator [3]
Target for Ferroptosis Suppressor
Responsed Disease Gestational diabetes ICD-11: JA63
Pathway Response Fatty acid metabolism hsa01212
Autophagy hsa04140
mTOR signaling pathway hsa04150
Cell Process Cell ferroptosis
Cell autophagy
In Vitro Model
HTR-8/SVneo cells Normal Homo sapiens CVCL_7162
pTr2 cells Normal Sus scrofa CVCL_YB18
Response regulation Upregulated SIRT3-enhanced autophagy activation by promoting AMPK-mTOR pathway and decreasing GPX4 level to induce ferroptosis in trophoblastic cells. SIRT3 deficiency was resistant to high glucose- and erastin-induced autophagy-dependent ferroptosis and is, therefore, a potential therapeutic approach for treating gestational diabetes mellitus (GDM).
Long-chain-fatty-acid--CoA ligase 4 (ACSL4) [Driver]
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis Target of This Regulator [4]
Target for Ferroptosis Driver
Responsed Disease Gallbladder cancer ICD-11: 2C13
Pathway Response Ferroptosis hsa04216
Cell adhesion molecules hsa04514
Cell Process Cell ferroptosis
Cell proliferation
Cell migration
Cell invasion
In Vitro Model
GBC-SD cells Gallbladder carcinoma Homo sapiens CVCL_6903
EH-GB1 cells Gallbladder carcinoma Homo sapiens CVCL_IU73
OCUG-1 cells Gallbladder carcinoma Homo sapiens CVCL_3083
NOZ cells Gallbladder carcinoma Homo sapiens CVCL_3079
In Vivo Model
Forty male BALB/cnude mice (4 weeks old, 15-16 g) were purchased from the Shanghai Laboratory Animal Center (Shanghai, China) and divided into eight groups. Cells (1.0 x 106) were subcutaneously injected into the leftaxillaof nude mice.

    Click to Show/Hide
Response regulation Expression levels of SIRT3 in patients with gallbladder cancer were lower than those in the adjacent normal tissue. Silence of SIRT3 gene also suppressed AKT-dependent ferroptosis, an iron-dependent and lipid peroxide-mediated cell death. Blockade of AKT activity in sh-SIRT3 cells induced ACSL4 expression that drives ferroptosis, and inhibited epithelial-mesenchymal (EMT) markers and invasive activity.
Gallbladder cancer [ICD-11: 2C13]
In total 1 item(s) under this disease
Experiment 1 Reporting the Ferroptosis-centered Disease Response [4]
Target Regulator NAD-dependent protein deacetylase sirtuin-3, mitochondrial (SIRT3) Protein coding
Pathway Response Ferroptosis hsa04216
Cell adhesion molecules hsa04514
Cell Process Cell ferroptosis
Cell proliferation
Cell migration
Cell invasion
In Vitro Model
GBC-SD cells Gallbladder carcinoma Homo sapiens CVCL_6903
EH-GB1 cells Gallbladder carcinoma Homo sapiens CVCL_IU73
OCUG-1 cells Gallbladder carcinoma Homo sapiens CVCL_3083
NOZ cells Gallbladder carcinoma Homo sapiens CVCL_3079
In Vivo Model
Forty male BALB/cnude mice (4 weeks old, 15-16 g) were purchased from the Shanghai Laboratory Animal Center (Shanghai, China) and divided into eight groups. Cells (1.0 x 106) were subcutaneously injected into the leftaxillaof nude mice.

    Click to Show/Hide
Response regulation Expression levels of SIRT3 in patients with gallbladder cancer were lower than those in the adjacent normal tissue. Silence of SIRT3 gene also suppressed AKT-dependent ferroptosis, an iron-dependent and lipid peroxide-mediated cell death. Blockade of AKT activity in sh-SIRT3 cells induced ACSL4 expression that drives ferroptosis, and inhibited epithelial-mesenchymal (EMT) markers and invasive activity.
Ovarian dysfunction [ICD-11: 5A80]
In total 1 item(s) under this disease
Experiment 1 Reporting the Ferroptosis-centered Disease Response [1]
Target Regulator NAD-dependent protein deacetylase sirtuin-3, mitochondrial (SIRT3) Protein coding
Responsed Drug Metformin Investigative
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vivo Model
n = 6 blank control group was created. The mice in the control group were fed regular food and gavaged with normal saline daily. The mice in the control group were given a high-fat diet and 1 mg/kg of letrozole via gavage for 21 days to establish a PCOS model of insulin resistance and hyperandrogenism. The mice, after successful modeling, were randomly divided into PCOS group and metformin group (n = 6). During the treatment period, the control group continued to be fed with normal feed and given normal saline; the PCOS group was fed with continuous high-fat feed and given letrozole (1 mg/kg/day) by intragastric administration, and the metformin group was given metformin by intragastric administration (200 mg/kg/day). After 30 days of treatment, the experimental mice were euthanized, serum was collected, one mouse ovary was collected for histological examination, and the other was stored in a -80 refrigerator for molecular biology experimental research.

    Click to Show/Hide
Response regulation Morphological results showed that after metformin treatment, polycystic lesions in ovaries were reduced, the ovarian function was restored, and the expressions of SIRT3 and GPX4 were elevated. Metformin could regulate ferroptosis to improve polycystic ovary syndrome (PCOS) via the SIRT3/AMPK/mTOR pathway.
Cardiomyopathy [ICD-11: BC43]
In total 1 item(s) under this disease
Experiment 1 Reporting the Ferroptosis-centered Disease Response [2]
Target Regulator NAD-dependent protein deacetylase sirtuin-3, mitochondrial (SIRT3) Protein coding
Responsed Drug LCZ696 Approved
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model
CHO-S/H9C2 cells Normal Cricetulus griseus CVCL_A0TS
In Vivo Model
All animal protocols were approved by the Animal Care and Use Committee of TaizhouHospital, affiliated to Zhejiang University (Taizhou, China). Twenty-four 2-month-old male Wistar rats weighing 190-220 g were purchased from the Experimental Animal Center of Basi Medicine, Zhejiang Chinese Medical University. The animals were reared under a 12 h light/12 h dark cycle at a relative humidity of 55 ± 5% and temperature of 23 ± 2 , with unrestricted access to food and water. All animals were acclimatized to laboratory conditions for 1 week before the experiments and were randomly divided into four groups: control group (CG, n = 6); LCZ696 group (LCZ, n = 6); DOX group (DOX, n = 6); and DOX + LCZ696 group (DOX + LCZ, n = 6). The CG received saline solution by gavage for 6 weeks (2 mL/day), while the treatment groups received DOX (Cat. HY-15142A, MedChemExpress, USA), LCZ696 (Cat. HY-18204A, MedChemExpress, USA), or DOX + LCZ696. DOX was administered at a dose of 2.5 mg/kg once a week for 6 weeks via tailvein injection. LCZ696 (60 mg/kg/day) was administered by gavage for 6 weeks. Body weight was measured weekly.

    Click to Show/Hide
Response regulation LCZ696 treatment increased SIRT3 expression and deacetylated its target gene SOD2, and these changes were mediated by AKT activation. Collectively,LCZ696 prevents DOX-induced cardiotoxicity by inhibiting ferroptosis via AKT/SIRT3/SOD2 signaling pathway activation.
Gestational diabetes [ICD-11: JA63]
In total 1 item(s) under this disease
Experiment 1 Reporting the Ferroptosis-centered Disease Response [3]
Target Regulator NAD-dependent protein deacetylase sirtuin-3, mitochondrial (SIRT3) Protein coding
Pathway Response Fatty acid metabolism hsa01212
Autophagy hsa04140
mTOR signaling pathway hsa04150
Cell Process Cell ferroptosis
Cell autophagy
In Vitro Model
HTR-8/SVneo cells Normal Homo sapiens CVCL_7162
pTr2 cells Normal Sus scrofa CVCL_YB18
Response regulation Upregulated SIRT3-enhanced autophagy activation by promoting AMPK-mTOR pathway and decreasing GPX4 level to induce ferroptosis in trophoblastic cells. SIRT3 deficiency was resistant to high glucose- and erastin-induced autophagy-dependent ferroptosis and is, therefore, a potential therapeutic approach for treating gestational diabetes mellitus (GDM).
Intervertebral disc degeneration [ICD-11: FA80]
In total 1 item(s) under this disease
Experiment 1 Reporting the Ferroptosis-centered Disease Response [5]
Target Regulator NAD-dependent protein deacetylase sirtuin-3, mitochondrial (SIRT3) Protein coding
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Ubiquitin mediated proteolysis hsa04120
Cell Process Cell ferroptosis
In Vitro Model
HEK-293T cells Normal Homo sapiens CVCL_0063
HNP (Human nucleus pulposus cells)
In Vivo Model
8-10 weeks old male mice were placed in prone position and anesthetized with isoflurane inhalation. The 1.5 cm-long longitudinal incision was made in 2 mm from the posterior midline. The superior and inferior articular processes, supraspinous ligament and interspinous ligament of the L4-L5 lumbar vertebrae were removed to construct LSI, which would induce IVDD. After the operation, the mice were placed in a warm environment.

    Click to Show/Hide
Response regulation Overexpression of USP11 significantly ameliorate oxidative stress-induced ferroptosis, thus relieving intervertebral disc degeneration (IVDD) by increasing Sirt3. Moreover, knockout of USP11 in vivo (USP11) resulted in exacerbated IVDD and poor pain-related behavioral scores, which could be reversed by overexpression of Sirt3 in intervertebral disc.
LCZ696 [Approved]
In total 1 item(s) under this drug
Experiment 1 Reporting the Ferroptosis-centered Drug Response [2]
Drug for Ferroptosis Suppressor
Response Target Unspecific Target
Responsed Disease Cardiomyopathy ICD-11: BC43
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model
CHO-S/H9C2 cells Normal Cricetulus griseus CVCL_A0TS
In Vivo Model
All animal protocols were approved by the Animal Care and Use Committee of TaizhouHospital, affiliated to Zhejiang University (Taizhou, China). Twenty-four 2-month-old male Wistar rats weighing 190-220 g were purchased from the Experimental Animal Center of Basi Medicine, Zhejiang Chinese Medical University. The animals were reared under a 12 h light/12 h dark cycle at a relative humidity of 55 ± 5% and temperature of 23 ± 2 , with unrestricted access to food and water. All animals were acclimatized to laboratory conditions for 1 week before the experiments and were randomly divided into four groups: control group (CG, n = 6); LCZ696 group (LCZ, n = 6); DOX group (DOX, n = 6); and DOX + LCZ696 group (DOX + LCZ, n = 6). The CG received saline solution by gavage for 6 weeks (2 mL/day), while the treatment groups received DOX (Cat. HY-15142A, MedChemExpress, USA), LCZ696 (Cat. HY-18204A, MedChemExpress, USA), or DOX + LCZ696. DOX was administered at a dose of 2.5 mg/kg once a week for 6 weeks via tailvein injection. LCZ696 (60 mg/kg/day) was administered by gavage for 6 weeks. Body weight was measured weekly.

    Click to Show/Hide
Response regulation LCZ696 treatment increased SIRT3 expression and deacetylated its target gene SOD2, and these changes were mediated by AKT activation. Collectively,LCZ696 prevents DOX-induced cardiotoxicity by inhibiting ferroptosis via AKT/SIRT3/SOD2 signaling pathway activation.
Metformin [Investigative]
In total 1 item(s) under this drug
Experiment 1 Reporting the Ferroptosis-centered Drug Response [1]
Drug for Ferroptosis Suppressor
Response Target Unspecific Target
Responsed Disease Ovarian dysfunction ICD-11: 5A80
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vivo Model
n = 6 blank control group was created. The mice in the control group were fed regular food and gavaged with normal saline daily. The mice in the control group were given a high-fat diet and 1 mg/kg of letrozole via gavage for 21 days to establish a PCOS model of insulin resistance and hyperandrogenism. The mice, after successful modeling, were randomly divided into PCOS group and metformin group (n = 6). During the treatment period, the control group continued to be fed with normal feed and given normal saline; the PCOS group was fed with continuous high-fat feed and given letrozole (1 mg/kg/day) by intragastric administration, and the metformin group was given metformin by intragastric administration (200 mg/kg/day). After 30 days of treatment, the experimental mice were euthanized, serum was collected, one mouse ovary was collected for histological examination, and the other was stored in a -80 refrigerator for molecular biology experimental research.

    Click to Show/Hide
Response regulation Morphological results showed that after metformin treatment, polycystic lesions in ovaries were reduced, the ovarian function was restored, and the expressions of SIRT3 and GPX4 were elevated. Metformin could regulate ferroptosis to improve polycystic ovary syndrome (PCOS) via the SIRT3/AMPK/mTOR pathway.
References
Ref 1 Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis. Front Endocrinol (Lausanne). 2023 Jan 23;14:1070264. doi: 10.3389/fendo.2023.1070264. eCollection 2023.
Ref 2 LCZ696 protects against doxorubicin-induced cardiotoxicity by inhibiting ferroptosis via AKT/SIRT3/SOD2 signaling pathway activation. Int Immunopharmacol. 2022 Dec;113(Pt A):109379. doi: 10.1016/j.intimp.2022.109379. Epub 2022 Oct 29.
Ref 3 SIRT3 deficiency is resistant to autophagy-dependent ferroptosis by inhibiting the AMPK/mTOR pathway and promoting GPX4 levels. J Cell Physiol. 2020 Nov;235(11):8839-8851. doi: 10.1002/jcp.29727. Epub 2020 Apr 24.
Ref 4 SIRT3 inhibits gallbladder cancer by induction of AKT-dependent ferroptosis and blockade of epithelial-mesenchymal transition. Cancer Lett. 2021 Jul 10;510:93-104. doi: 10.1016/j.canlet.2021.04.007. Epub 2021 Apr 16.
Ref 5 The deubiquitinase USP11 ameliorates intervertebral disc degeneration by regulating oxidative stress-induced ferroptosis via deubiquitinating and stabilizing Sirt3. Redox Biol. 2023 Jun;62:102707. doi: 10.1016/j.redox.2023.102707. Epub 2023 Apr 20.